- Home
- HLP vs ONCY Comparison
HLP vs ONCY Comparison
Compare HLP & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- ONCY
- Stock Information
- Founded
- HLP 2021
- ONCY 1998
- Country
- HLP China
- ONCY Canada
- Employees
- HLP N/A
- ONCY N/A
- Industry
- HLP Industrial Machinery/Components
- ONCY Pharmaceuticals and Biotechnology
- Sector
- HLP Industrials
- ONCY Health Care
- Exchange
- HLP Nasdaq
- ONCY Nasdaq
- Market Cap
- HLP 102.1M
- ONCY 89.7M
- IPO Year
- HLP 2023
- ONCY 1999
- Fundamental
- Price
- HLP $1.34
- ONCY $1.16
- Analyst Decision
- HLP
- ONCY Strong Buy
- Analyst Count
- HLP 0
- ONCY 5
- Target Price
- HLP N/A
- ONCY $5.00
- AVG Volume (30 Days)
- HLP 301.9K
- ONCY 1.0M
- Earning Date
- HLP 05-15-2026
- ONCY 11-11-2025
- Dividend Yield
- HLP N/A
- ONCY N/A
- EPS Growth
- HLP N/A
- ONCY N/A
- EPS
- HLP 0.02
- ONCY N/A
- Revenue
- HLP $16,731,357.00
- ONCY N/A
- Revenue This Year
- HLP N/A
- ONCY N/A
- Revenue Next Year
- HLP N/A
- ONCY N/A
- P/E Ratio
- HLP $63.94
- ONCY N/A
- Revenue Growth
- HLP 19.13
- ONCY N/A
- 52 Week Low
- HLP $0.61
- ONCY $0.33
- 52 Week High
- HLP $1.82
- ONCY $1.51
- Technical
- Relative Strength Index (RSI)
- HLP 52.11
- ONCY 44.07
- Support Level
- HLP $1.40
- ONCY $1.10
- Resistance Level
- HLP $1.54
- ONCY $1.26
- Average True Range (ATR)
- HLP 0.15
- ONCY 0.07
- MACD
- HLP -0.04
- ONCY -0.02
- Stochastic Oscillator
- HLP 10.26
- ONCY 21.54
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.